Develops umbilical cord–derived allogeneic stem-cell therapies for inflammation-driven degenerative diseases; flagship product CARTISTEM treats knee cartilage lesions and is in late-stage U.S. development for osteoarthritis. Partnership created a cell‑and‑gene therapy CDMO to manufacture CARTISTEM.